Crescent Biopharma vs Janux Therapeutics
CBIO and JANX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBIO and JANX compare
Janux Therapeutics is the larger company, worth 1.3 times as much as Crescent Biopharma ($695M against $526M).
Janux Therapeutics keeps more of each dollar of sales as profit, with a net margin of −429% compared with −728% at Crescent Biopharma.
Janux Therapeutics scores higher on the StockData Score (12 against 10 for Crescent Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBIO | JANX |
|---|---|---|
| Size and price | ||
| Market cap | $526M | $695M |
| Share price | $14.15 | $11.37 |
| Change, 1 year | 8.4% | −60.1% |
| Change, 5 years | −92.5% | −36.4% |
| Beta (5Y) | 1.63 | 1.60 |
| Employees | 44 | 109 |
| StockData Score | ||
| Total score | 10 | 12 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 35.0× | 29.8× (better) |
| P/B | 1.9× | 0.8× (better) |
| FCF yield | −15.7% | −7.8% (better) |
| Fair value | – | $16.54 |
| Margin of safety | – | 31.3% |
| Growth | ||
| Revenue growth (TTM) | – | 133% |
| Revenue growth, 5Y average | 1.3% | – |
| Profitability | ||
| Operating margin | −1217% | −599% (better) |
| Net margin | −728% | −429% (better) |
| FCF margin | −550% | −233% (better) |
| Return on equity | −55.8% | −10.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 12.57 | 17.69 (better) |
| Altman Z-score | 10.43 (better) | 5.85 |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 79.7% | 101% |
| Held by insiders | 38.6% | 21.3% |
| Insider net buying, 12 months | $29.1M (better) | −$457K |
| Short interest, % of float | 18.3% | 11.1% |
Go deeper
- CBIO stock overview
- CBIO income statement
- CBIO valuation and score
- JANX stock overview
- JANX income statement
- JANX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.